Law Offices of Howard G. Smith announces an investigation on behalf of Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN) investors concerning the Company’s possible violations of federal securities laws.
Ocugen is a biopharmaceutical company. Pursuant to an agreement with Bharat Biotech, Ocugen has the exclusive right to develop, manufacture, and commercialize COVAXIN, a vaccine candidate for COVID-19.
On June 10, 2021, Ocugen announced that it would submit a biologics license application (“BLA”) for COVAXIN, which has a longer approval process than an Emergency Use Authorization (“EUA”) application, and that it anticipated conducting an additional clinical trial to support the submission.
On this news, the Company’s share price fell $2.62 per share, or 28%, to close at $6.69 per share on June 10, 2021, thereby injuring investors.
If you purchased Ocugen securities, have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to firstname.lastname@example.org, or visit our website at www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.